Rocket One Inc. Common Stock (NASDAQ:RKTO) Announces Earnings Results

Rocket One Inc. Common Stock (NASDAQ:RKTO) issued its quarterly earnings results on Friday. The company reported ($0.11) EPS for the quarter, FiscalAI reports.

Rocket One Inc. Common Stock Trading Down 7.0%

RKTO traded down $0.02 on Friday, hitting $0.32. 219,607 shares of the company’s stock were exchanged, compared to its average volume of 332,302. The stock has a fifty day moving average of $0.60 and a two-hundred day moving average of $0.82. Rocket One Inc. Common Stock has a twelve month low of $0.32 and a twelve month high of $2.45. The firm has a market cap of $7.99 million, a PE ratio of -0.39 and a beta of 1.01.

Institutional Trading of Rocket One Inc. Common Stock

A hedge fund recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC lifted its position in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 39,000 shares of the company’s stock after acquiring an additional 19,500 shares during the period. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent filing with the SEC. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RKTO has been the topic of several analyst reports. Wall Street Zen upgraded Rocket One Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Sunday, October 25th. Weiss Ratings upgraded Rocket One Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Rocket One Inc. Common Stock currently has an average rating of “Hold” and a consensus price target of $5.00.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.